



PEIA Public Hearings for FY 23 (July 2022 – June 2023)

November 2021

PEIA FY 2023 PLAN DISCUSSION

PREMIUMS

- State Fund Employees
 - No Change in '23
 - Governor has pledged funding to prevent the premium increases reflected in '24
- Non-State Fund
 - 5% premium increase
- Non-Medicare Retirees
 - No Change
- Medicare Retirees - January 2022 (current plan year reduction)
 - 19% premium decrease (percentages vary by policy and years of service tier and tobacco status)
- Medicare Retirees – January 2023
 - No Change

PEIA

Five Year Plan

	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Additional Employer Premium	\$ -	\$ -	\$ 45,000,000	\$ 83,000,000	\$ 73,500,000
Increase	0%	0%	9%	15%	12%
Local Fund Premium Increase	\$ -	\$ 7,500,000	\$ 18,500,000	\$ 20,500,000	\$ 21,500,000
Increase	0%	5%	12%	12%	10%
Employee Premium	\$ -	\$ -	\$ 11,300,000	\$ 20,800,000	\$ 18,400,000
Increase	0%	0%	9%	16%	12%
State Direct Transfer (State Budget Appropriations)	\$ 21,000,000	\$ 21,000,000	\$ 21,000,000	\$ 21,000,000	\$ 21,000,000
State Direct Transfer (PEIA Rainy Day Fund)	\$ -	\$ 31,000,000	\$ -	\$ -	\$ -
Board Decision Benefit Reduction - Active State Medical					
Board Decision Benefit Reduction - Active State Drugs					
Board Decision Benefit Reduction - Active Local Medical					
Board Decision Benefit Reduction - Active Local Drugs					
ACA PCORI Fees (Cost)	\$ (448,679)	\$ (448,686)	\$ (448,686)	\$ (448,686)	\$ (448,686)
Pay Go Premium Transfer	\$ 75,000,000	\$ 60,000,000	\$ 20,000,000	\$ 30,000,000	\$ 40,000,000
Total Fund	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
State Reserve	161,477,148	136,006,699	110,352,813	114,043,744	125,203,676
Local Reserve	38,927,195	25,909,969	25,556,105	27,737,126	30,828,944
RHBT Reserve	268,106,504	266,817,032	213,614,413	158,822,581	101,058,020
Total Reserve	468,510,847	428,733,700	349,523,331	300,603,451	257,090,640
Minimum Actuarial Reserve Required	133,729,518	139,107,856	151,556,871	165,914,776	182,603,011
PEIA/RHBT Expenses	954,503,328	985,325,329	1,072,593,111	1,172,510,904	1,288,024,638
Reserve as a Percent of Expenses	49%	44%	33%	26%	20%
State Fund	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Beginning Reserve	192,310,986	161,477,148	136,006,699	110,352,814	114,043,744
Fiscal Year Results	(30,833,838)	(25,470,449)	(25,653,886)	3,690,930	11,159,932
Ending Reserve	161,477,148	136,006,699	110,352,813	114,043,744	125,203,676
Minimum Actuarial Reserve Required	89,737,301	95,051,279	103,390,057	113,118,814	124,506,538
PEIA/RHBT Expenses	623,399,689	660,130,717	717,102,108	783,419,788	860,882,122
Reserve as a Percent of Expenses	26%	21%	15%	15%	15%
Local Fund	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Beginning Reserve	53,227,644	38,927,195	25,909,969	25,556,105	27,737,126
Fiscal Year Results	(14,300,449)	(13,017,226)	(353,864)	2,181,021	3,091,818
Ending Reserve	38,927,195	25,909,969	25,556,105	27,737,126	30,828,944
Minimum Actuarial Reserve Required	21,923,392	23,230,089	25,270,639	27,654,431	30,447,629
PEIA/RHBT Expenses	149,555,768	158,427,187	172,199,980	188,270,679	207,081,061
Reserve as a Percent of Expenses	26%	16%	15%	15%	15%
State Share	80.3%	80.3%	80.3%	80.2%	80.2%
Employee Share	19.7%	19.7%	19.7%	19.8%	19.8%
Growth In Program Expenses	-1.2%	3.6%	3.5%	10.2%	10.6%

RHBT

Five Year Plan

	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Retiree Premium Increase- Non-Medicare (Fiscal Year)	\$ -	\$ -	\$ 1,246,086	\$ 1,256,834	\$ 1,265,886
Increase	0.0%	0.0%	5.0%	5.0%	5.0%
Retiree Premium Increase - Medicare (Calendar Year)	\$ (8,074,681)	\$ -	\$ 3,960,699	\$ 4,237,890	\$ 4,581,102
Increase	-19.5%	0.0%	5.0%	5.0%	5.0%
General Revenue Transfer (OPEB Funding)	\$ 30,000,000	\$ 30,000,000	\$ 30,000,000	\$ 30,000,000	\$ 30,000,000
General Revenue Transfer (Premium Offset)	\$ -	\$ -	\$ -	\$ -	\$ -
Board Decision Benefit Reduction - Retiree Non-Medicare					
Board Decision Benefit Reduction - Retiree Medicare					
Board Decision Benefit Reduction - Humana MAPD (Calendar Year)	\$ 34,784,854	\$ 34,209,468			
ACA PCORI Fees (Cost)	\$ (14,712)	\$ (15,814)	\$ (16,938)	\$ (18,059)	\$ (19,179)
Pay Go Premium Transfer	\$ 75,000,000	\$ 60,000,000	\$ 20,000,000	\$ 30,000,000	\$ 40,000,000
Total RHBT Fund	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Beginning Reserve	\$ 1,671,342,325	\$ 1,827,877,921	\$ 1,993,092,377	\$ 2,118,764,710	\$ 2,252,339,871
Fiscal Year Results	(43,464,405)	167,875,384	180,352,767	189,873,985	199,998,451
Ending Total Reserve	1,827,877,921	1,993,092,377	2,118,764,710	2,252,339,871	2,393,038,522
Ending Premium Stabilization Reserve	\$ 268,106,504	\$ 265,445,577	\$ 210,765,142	\$ 154,466,319	\$ 95,166,518
Medicare Fund (Fiscal Year)	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Beginning Reserve	\$ 923,720,234	\$ 1,030,283,212	\$ 1,145,264,030	\$ 1,245,276,438	\$ 1,354,390,261
Fiscal Year Results	(53,184,550)	117,105,175	143,645,545	154,016,616	165,521,138
Ending Total Reserve	1,030,283,212	1,145,264,030	1,245,276,438	1,354,390,261	1,472,638,044
Ending Premium Stabilization Reserve	\$ 207,239,133	\$ 205,114,776	\$ 161,481,639	\$ 116,578,846	\$ 69,305,491
Non-Medicare Fund	<u>2022</u>	<u>2023</u>	<u>2024</u>	<u>2025</u>	<u>2026</u>
Beginning Reserve	\$ 747,622,091	\$ 797,594,710	\$ 847,828,348	\$ 873,488,273	\$ 897,949,611
Fiscal Year Results	9,720,147	50,770,208	36,707,222	35,857,369	34,477,312
Ending Total Reserve	797,594,710	847,828,348	873,488,273	897,949,611	920,400,478
Ending Premium Stabilization Reserve	\$ 60,867,371	\$ 60,330,801	\$ 49,283,503	\$ 37,887,473	\$ 25,861,027
*Actuarial Accrued Liability	\$ 1,663,727,440	\$ 1,686,322,024	\$ 1,704,800,458	\$ 1,715,909,460	\$ 1,719,565,219
Funded Status	100.5%	108.4%	116.9%	123.5%	131.0%
Growth In Program Expenses	-14.4%	-8.1%	9.9%	9.6%	9.6%
Retiree Subsidy	\$ 103,121,120	\$ 92,690,138	\$ 106,211,107	\$ 119,406,029	\$ 134,062,366
Percent Paid By Retiree	41.5%	42.6%	40.3%	38.9%	37.6%

* Estimated Result

BENEFITS

- PEIA is reviewing proposals from Life Insurance carriers for the basic and optional life benefits effective July 1, 2022
- Various disease management and wellness programs now offered. Please watch for opportunities to sign up for these programs:
 - ‘Wondr’ weight management program
 - SWORD virtual physical therapy pilot program
- Due to Covid-19’s impact on healthcare delivery, PEIA offers more telehealth benefits along with traditional visits
- In accordance with updated clinical guidelines, PEIA has lowered the colon cancer screening age to 45 and age 50 for lung cancer screening
- PEIA will change Pharmacy Benefit Managers (PBM) for FY ’23 to Express Scripts after issuing an RFP July 2021
 - New PBM will be effective July 1, 2022
 - A new combined medical/prescription ID card will be provided in June 2022
 - Same pharmacy benefits: deductible, copays, co-insurance, out-of-pocket maximum as today
 - Same broad network of WV and out-of-state pharmacies as today
 - There will be formulary changes due to this change
 - Member and doctor will receive letters
 - See most common changes on following pages
 - Rising drug costs drive PEIA to rebid the PBM contract to assure best pricing

ESI FORMULARY CHANGES

Drug Name	Therapeutic Category	Current Formulary Tier	Proposed Formulary Tier	Preferred Formulary Alternatives
ACCU-CHEK GUIDE TEST STRIP	DIABETES	Tier 2	Excluded	FREESTYLE TEST STRIPS, FREESTYLE LITE TEST STRIP, FREESTYLE INSULINX TEST STRIPS, PRECISION XTRA, ONETOUGH ULTRA BLUE TEST STRP, ONETOUGH VERIO TEST STRIP
ACCU-CHEK AVIVA PLUS	DIABETES	Tier 2	Excluded	FREESTYLE TEST STRIPS, FREESTYLE LITE TEST STRIP, FREESTYLE INSULINX TEST STRIPS, PRECISION XTRA, ONETOUGH ULTRA BLUE TEST STRP, ONETOUGH VERIO TEST STRIP
SUPREP	CONSTIPATION	Tier 2	Excluded	GAVILYTE-G, PEG-3350 AND ELECTROLYTES, PEG3350-SOD SUL-NACL-KCL-ASB-C, TRILYTE WITH FLAVOR PACKETS
NOVOLOG FLEXPEN	DIABETES	Tier 2	Excluded	HUMALOG KWIKPEN U-100
CIPRODEX	EAR INFECTION	Tier 2	Tier 3	CIPROFLOXACIN-DEXAMETHASONE
BASAGLAR KWIKPEN U-100	DIABETES	Tier 2	Tier 3	LEVEMIR, LEVEMIR FLEXTOUCH, TOUJEO SOLOSTAR, TRESIBA FLEXTOUCH U-200, TRESIBA FLEXTOUCH U-100, SEMGLEE
ADDERALL XR	ATTENTION DISORDERS	Tier 2	Tier 3	DEXTROAMPHETAMINE-AMPHET ER
LO LOESTRIN FE	CONTRACEPTIVES	Tier 2	Excluded	BLISOVI FE, BLISOVI 24 FE, HAILEY FE, JUNEL FE 24, LARIN FE, MELODETTA 24 FE, NORETHINDRONE-E.ESTRADIOL-IRON
NOVOLOG	DIABETES	Tier 2	Excluded	HUMALOG
VICTOZA 3-PAK	DIABETES	Tier 2	Excluded	BYDUREON BCISE, BYETTA, OZEMPIC, TRULICITY
CONCERTA	ATTENTION DISORDERS	Tier 2	Excluded	METHYLPHENIDATE HCL ER (CD)
EPINEPHRINE	ANAPHYLAXIS	Tier 1	Excluded	EPINEPHRINE, EPIPEN
TRINTELLIX	DEPRESSION	Tier 2	Tier 3	CITALOPRAM HBR, ESCITALOPRAM OXALATE, FLUOXETINE HCL, FLUVOXAMINE MALEATE, PAROXETINE HCL, SERTRALINE HCL
EPIDUO FORTE	ACNE	Tier 2	Excluded	ADAPALENE/ BENZOYL PEROXIDE
DUREZOL	OPHTHALMIC CONDITIONS	Tier 2	Tier 3	DEXAMETHASONE SODIUM PHOSPHATE, FLUOROMETHOLONE, LOTEPREDNOL ETABONATE, PREDNISOLONE ACETATE INVELTYS, LOTEMAX
PREMARIN	HORMONAL SUPPLEMENTATION	Tier 2	Excluded	ESTRADIOL TABLETS
PAZEO	OPHTHALMIC CONDITIONS	Tier 2	Excluded	AZELASTINE HCL, CROMOLYN SODIUM, EPINASTINE HCL, OLOPATADINE HCL ZERVIATE
MESALAMINE ER	INFLAMMATORY CONDITIONS	Tier 1	Excluded	APRISO
LEVALBUTEROL TARTRATE HFA	ASTHMA	Tier 1	Excluded	ALBUTEROL SULFATE HFA
AMITIZA	GI DISORDERS	Tier 2	Excluded	LINZESS, TRULANCE
DEXILANT	HEARTBURN/ULCER DISEASE	Tier 2	Tier 3	ESOMEPRAZOLE MAGNESIUM, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE SODIUM, RABEPRAZOLE SODIUM
DOXYCYCLINE IR-DR	SKIN CONDITIONS	Tier 1	Excluded	DOXYCYCLINE HYCLATE, DOXYCYCLINE MONOHYDRATE
VICTOZA 2-PAK	DIABETES	Tier 2	Excluded	BYDUREON BCISE, BYETTA, OZEMPIC, TRULICITY
PRALUENT PEN	HIGH BLOOD CHOLESTEROL	Tier 2	Excluded	REPATHA SURECLICK
VRAYLAR	MENTAL/NEURO DISORDERS	Tier 2	Tier 3	ARIPIPRAZOLE, ASENAPINE MALEATE, OLANZAPINE, QUETIAPINE FUMARATE, RISPERIDONE, ZIPRASIDONE HCL, LATUDA
SOOLANTRA	SKIN CONDITIONS	Tier 2	Tier 3	AZELAIC ACID, METRONIDAZOLE, METRONIDAZOLE, METRONIDAZOLE, ROSULA FINACEA
PREMPRO	HORMONAL SUPPLEMENTATION	Tier 2	Excluded	ESTRADIOL/ NORETHINDRONE ACETATE, ETHINYL ESTRADIOL/ NORETHINDRONE ACETATE
PULMICORT FLEXHALER	ASTHMA	Tier 2	Excluded	ARNUITY ELLIPTA, ASMANEX, ASMANEX HFA, FLOVENT DISKUS, FLOVENT HFA, QVAR REDHALER
SUCRALFATE	HEARTBURN/ULCER DISEASE	Tier 1	Excluded	

Drug Name	Therapeutic Category	Current Formulary Tier	Proposed Formulary Tier	Preferred Formulary Alternatives
CLENPIQ	CONSTIPATION	Tier 2	Excluded	GAVILYTE-G, PEG-3350 AND ELECTROLYTES, PEG3350-SOD SUL-NACL-KCL-ASB-C, TRILYTE WITH FLAVOR PACKETS
DRYSOL	SKIN CONDITIONS	Tier 3	Excluded	CERTAIN, BROMI-LOTION
COLCHICINE	GOUT	Tier 1	Excluded	COLCHICINE TABLETS, MITIGARE
PROCTOFOAM-HC	RECTAL DISORDERS	Tier 2	Excluded	HYDROCORTISONE-PRAMOXINE, HYDROCORTISONE-PRAMOXINE
INTRAROSA	VAGINAL DISORDERS	Tier 3	Excluded	ESTRADIOL, ESTRADIOL, YUVAFEM
TROKENDI XR	SEIZURES	Tier 2	Tier 3	TOPIRAMATE, QUDEXY XR
ACCU-CHEK SMARTVIEW	DIABETES	Tier 2	Excluded	FREESTYLE TEST STRIPS, FREESTYLE LITE TEST STRIP, FREESTYLE INSULINX TEST STRIPS, PRECISION XTRA, ONETOUCH ULTRA BLUE TEST STRP, ONETOUCH VERIO TEST STRIP
NOVOLOG MIX 70-30 FLEXPEN	DIABETES	Tier 2	Excluded	HUMALOG MIX 75-25
COSENTYX PEN (2 PENS)	INFLAMMATORY CONDITIONS	Tier 2	Excluded	TALTZ AUTOINJECTOR, ENBREL, HUMIRA(CF) PEN, OTEZLA, SKYRIZI (2 SYRINGES) KIT, STELARA, TREMFYA
FOCALIN XR	ATTENTION DISORDERS	Tier 3	Excluded	DEXMETHYLPHENIDATE HCL ER
TRUVADA	HIV	Tier 2	Excluded	EMTRICITABINE-TENOFOVIR DISOP
NOVOLIN N	DIABETES	Tier 2	Excluded	HUMULIN N
NUVARING	CONTRACEPTIVES	Tier 2	Tier 3	ELURYNG, ETONOGESTREL-ETHINYL ESTRADIOL
ILEVRO	OPHTHALMIC CONDITIONS	Tier 2	Tier 3	BROMFENAC SODIUM, DICLOFENAC SODIUM, KETOROLAC TROMETHAMINE
DAPSONE	ACNE	Tier 1	Tier 3	
NOVOLIN R	DIABETES	Tier 2	Excluded	HUMULIN R
NURTEC ODT	MIGRAINE HEADACHES	Tier 2	Tier 3	ALMOTRIPTAN MALATE, ELETRIPTAN HBR, FROVATRIPTAN SUCCINATE, NARATRIPTAN HCL, RIZATRIPTAN, SUMATRIPTAN SUCCINATE
TECFIDERA	MULTIPLE SCLEROSIS	Tier 2	Tier 3	DIMETHYL FUMARATE
LYRICA	PAIN/INFLAMMATION	Tier 2	Excluded	PREGABALIN
SUBOXONE	CHEMICAL DEPENDENCE	Tier 3	Excluded	BUPRENORPHINE/ NALOXONE
ESTRING	VAGINAL DISORDERS	Tier 2	Excluded	ESTRADIOL CREAM, ESTRADIOL VAGINAL INSERTS, PREMARIN CREAM
PROLIA	OSTEOPOROSIS	Tier 2	Excluded	alendronate, ibandronate, risdronate, zoledronic acid, FORTEO, TYMLOS
COPAXONE	MULTIPLE SCLEROSIS	Tier 2	Tier 3	GENERIC
HUMATROPE	GROWTH DEFICIENCY	Tier 2	Excluded	GENOTROPIN, NORDITROPIN FLEXPRO
KEVZARA	INFLAMMATORY CONDITIONS	Tier 2	Excluded	ENBREL, HUMIRA, OTEZLA, RINVOQ ER, SKYRIZI, STELARA SC, TALTZ, TREMFYA, XELJANZ, XELJANZ XR
ORENCIA CLICKJECT	INFLAMMATORY CONDITIONS	Tier 2	Excluded	ENBREL, HUMIRA, OTEZLA, RINVOQ ER, SKYRIZI, STELARA SC, TALTZ, TREMFYA, XELJANZ, XELJANZ XR
AMPYRA	MULTIPLE SCLEROSIS	Tier 3	Excluded	GENERIC
NEULASTA	BLOOD CELL DEFICIENCY	Tier 2	Excluded	FULPHILA, ZIEXTENZO
ATRIPLA	HIV	Tier 2	Excluded	GENERIC
PIQRAY	CANCER	Tier 3	Excluded	IBRANCE, VERZENIO
LETAIRIS	PULMONARY HYPERTENSION	Tier 3	Excluded	GENERIC

UMR INTERNET TOOLS



West Virginia PEIA – Consumer Cost & Quality Transparency Strategy

Commitment to member education

- As a key component to managing healthcare costs and driving better outcomes for care delivered to our members, PEIA has made an ongoing commitment to educate benefit plan participants on the importance of cost and quality when making healthcare purchasing decisions.
- PEIA has negotiated reduced, flat reimbursement rates for many common healthcare services on behalf of benefit participants.
- To make the most of these commitments, PEIA has worked directly with United Healthcare/UMR to provide access to a custom Provider Search & Cost/Quality Transparency tool.

The Provider Search & Cost/Quality Transparency tool is available now! Easily accessible for PPB plan members by registering and logging in at:

www.umar.com

PPB Plan members can also use the specially trained Plan Advisor advocates for any help they may require by calling:

(888) 440-7342





West Virginia PEIA – Consumer Cost & Quality Transparency Strategy

The tool:


- Allows searches by provider, place, services, treatments and even by condition
- Has an easy natural language search process (i.e. enter simple terms like “knee pain” or “childbirth” to see available care and provider details)
- Automatically uses member’s home zip code, but allows searches anywhere in the US
- Produces detailed search results showing WV providers, as well as in-network providers outside the state, with both cost and quality ratings
- Includes easy indicators of providers who meet the United Healthcare “Premium Designation” guidelines and performance requirements for quality outcomes and cost efficiency.
- Shows detailed patient/consumer ratings through a nationwide partnership with Healthgrades.
- Allows plan participants to create detailed cost estimates based on actual negotiated rates and specific benefit plans.

The Provider Search & Cost/Quality Transparency tool is available now! Easily accessible for PPB plan members by registering and logging in at:

www.umar.com

PPB Plan members can also use the specially trained Plan Advisor advocates for any help they may require by calling:

(888) 440-7342



QUESTIONS AND PUBLIC COMMENTS

- Please limit your time to 5 minutes.